Profile

Research

Publications

Team

Alumni

Nirmalya Sen, PhD

Ramalingaswami Faculty Fellow

+91-7593820995

nirmalya@rgcb.res.in

NirmalyaSen
NirmalyaSen

Nirmalya Sen, PhD

Ramalingaswami Faculty Fellow

+91-7593820995

nirmalya@rgcb.res.in

  • Profile

    • Ph.D National Institute of Immunology, New Delhi, India
    • M.Sc Banaras Hindu University, Department of Biochemistry
    • B.Sc Banaras Hindu University, Faculty of Science
    • Diploma: Statistical methods, Banaras Hindu University
    • 2018-Present: DBT Ramalingaswmi Faculty fellow, RGCB, Thiruvananthapuram
    • 2014-2017: Visiting Fellow , National Cancer Institute, NIH, Bethesda
    • 2013-2014: Post-Doctoral Scientist, George Washington University, Washington DC
    • 2008-2013: PhD, National Institute of Immunology, New Delhi
    • 2007: Summer Research Fellowship, INSA, Bose Institute, Kolkata
    • DBT Ramalingaswami Fellowship (2018)
    • Visiting Fellow (CRTA), NCI, NIH 2015-2017
    • DBT Travel Grant 2013, CSIR Foreign Travel Grant 2013
    • Senior Research Fellow, CSIR 2011-2013 , Junior Research Fellow, CSIR 2008-2010
    • Summer Research Fellowship, INSA 2007
    • AmericanAssociation for Cancer Research Peer Reviewer in international journals :
    • Cancer research (2014-present),
    • Oncogene (2014-present)
    • Scientific reports (2017- present)
    • The journal of Pathology (2017-present)
  • Research

    Regulation of ETS transcription factor in refractory cancer model

    My area of research is regulation of transcription factors in cancers. Till date no drug exists which can directly target transcription factors that are primary drivers of many cancers. The laboratory studies, ETS (E-Twenty-Six) family of transcriptional factors, a group of 27 family members with a conserved DNA binding ETS domain. ETS transcription factors are aberrantly over-expressed and mediate cancer progression through altered transcription of their target genes such as FLI1 in hematological malignancies, ERG in prostate cancer. Moreover, ETS factors generate oncogenic fusion genes through chromosomal translocation such as EWS-FLI1 fusion in Ewing sarcomas, TMPRSS2-ERG and TMPRSS2 ETV1 fusions in prostate cancer, which acts as drivers in these cancers. The lab will be studying posttranslational modifications (PTMs like phosphorylation, ubiquitination, acetylation, etc) within the ETS protein that are crucial for the stability and function of these protein and can provide excellent therapeutic targets even in the fusion counterpart. We are using prostate cancer to model our studies. Most of our current studies will be based on two prostate cancer specific ETS transcription factor regulation; namely ETV1 and ERG.

    research

    We will use the latest molecular biological techniques ranging from mass spectroscopy to sequencing as well as mouse based studies to figure out the role of these ETS factors during progression of prostate cancer. The project tends to capture various aspects of hormone independent resistance prostate cancer including metabolic reprogramming, clinical intervention, DNA damage and drug resistance, patient derived models of prostate cancer in future.

    Ramalingaswami Fellowship, Department of Biotechnology (2018-2023)

  • Publications

    Publications

    1. Nirmalya Sen, Allison M. Cross, Philip L. Lorenzi, Javed Khan, Berkley E. Gryder, Suntae Kim, Natasha J. Caplen. EWS-FLI1 reprograms the metabolism of Ewing sarcoma cells via positive regulation of glutamine import and serine glycine biosynthesis. Molecular Carcinogenesis. Under communication.
    2. Berkley E. Gryder , Marielle E. Yohe , Nirmalya Sen , Hsien-Chao Chou , Xiaohu Zhang , Joana Marques , Marco Watchte , Beat Schaefer , Alberto Gualtieri , Silvia Pomella , Rossella Rota , Young K. Song , Abigail Cleveland , Xinyu Wen , Mr. Sivasish Sindiri , Jun S. Wei , Frederic G. Barr , Rajarshi Guha , Madhu Lal-Nag , Marc Ferrer , Thorkell Andresson , Jack F. Shern , Keji Zhao , Craig J. Thomas, Javed Khan. PAX3-FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability. Cancer Discovery, Volume 7, Issue 8, p884-899, August 1, 2017.
    3. Patrick J. Grohar, Suntae Kim, Guillermo O. Rangel Rivera, Nirmalya Sen, Sara Haddock, Matt L. Harlow, Nichole K. Maloney, Jack Zhu, Maura O’Neill, Tamara L. Jones, Konrad Huppi, Magdalena Grandin, Kristen Gehlhaus, Carleen A. Klumpp-Thomas, Eugen Buehler, Lee J. Helman, Scott E. Martin, and Natasha J. Caplen. Functional Genomic Screening Reveals Splicing of the EWS-FLI1 Fusion Transcript as Vulnerability in Ewing Sarcoma. Cell Reports, Volume 14, Issue 3, p598–610, 26 January 2016
    4. Nirmalya Sen, Gui Bin, Rakesh Kumar. Role of MTA1 in cancer progression and metastasis. Cancer Metastasis Rev. 2014 Dec;33(4):879-89.
    5. Nirmalya Sen, Gui Bin, Rakesh Kumar. Physiological functions of MTA family of proteins. Cancer Metastasis Rev. 2014 Dec;33(4):869-77.
    6. Rajni Kumari, Nirmalya Sen and Sanjeev Das. Tumour suppressor p53: understanding the molecular mechanisms inherent to cancer. Current Science, Vol. 107, August 2014
    7. Nirmalya Sen, Rajni Kumari, Manika Inderjit Singh and Sanjeev Das. HDAC5, a Key Component in Temporal Regulation of p53-Mediated Transactivation in Response to Genotoxic Stress. Molecular Cell, Volume 52, Issue 3, 406-420, 10 October 2013.
    8. Nirmalya Sen, Yatendra Kumar Satija and Sanjeev Das. p53 and metabolism: Old player in a new game. Transcription, Volume 3, Issue 3, 119 – 123, May/June 2012.
    9. Nirmalya Sen, Yatendra Kumar Satija and Sanjeev Das. PGC-1α, a Key Modulator of p53, Promotes Cell Survival upon Metabolic Stress. Molecular Cell, Volume 44, Issue 4, 621-634, 18 November 2011
  • Team


  • Alumni